RGNX News and Press, REGENXBIO Inc. From 02/29/24

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial PR Newswire Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapa...

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PR Newswire Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Prioritized pipeline is expec...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-23 03:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will...

2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...

2024-02-12 04:47:00 ET Summary For the week just past, the S&P 500 was up 1.4%. Even though Magnificent 7 stocks continue to lead the market higher, market participation is broadening out, which is a healthy sign. The ProShares Bitcoin Strategy ETF took the top spot on the...

2024-02-07 12:48:15 ET More on Regenxbio Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Seeking Alpha’s Quant Rating on Regenxbio Historical earnings data for Regenxbio Financial information for Regenxbio Read the fu...

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint PR Newswire Results support BLA submission in 2024 using the accelerated approval pathway Primary endpoint of patients achieving reduction in CSF biomarker of MPS II di...

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial PR Newswire Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE ® trial of RGX-202, a potential one-time AAV Therapeutic f...